U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133308) titled 'Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata' on July 29.
Brief Summary: This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Study Start Date: Aug. 05
Study Type: INTERVENTIONAL
Condition:
Alopecia Areata
Intervention:
DRUG: Deuruxolitinib
Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
DRUG: Placebo
Deuruxolitinib matching placebo will be dosed orally as tablets
Recruitment Status: RECRUITING
Sponsor: Sun Pharmaceutical Industries, Inc.
Published...